Tajima Ken

Affiliation and department：

Research field (2)： Tumor diagnostics and therapeutics , Respiratory medicine

Research keywords (7)：細胞老化 , 抗がん剤耐性 , 上皮間葉転換 , ヒストンメチル化 , エピジェネティクス , 肺がん , 中皮腫

Research theme for competitive and other funds (12)：

2023 - 2027 薬剤耐性クローンに着目した腫瘍内不均一性と薬剤耐性原理の解明
2023 - 2026 エピジェネティクスの再構成の追跡による老化細胞の分類構築と新規治療法開発への挑戦
2023 - 2026 肺癌における酸化ストレス応答系の新規破綻機序の解明と標的治療の探索
2021 - 2025 中皮腫における細胞系譜構築による新規治療法の探究と臨床応用
2021 - 2024 肺癌における糖鎖分子を標的としたEGFR-TKI耐性克服の試み

Show all

Papers (41)：

Koichiro Kanamori, Kentaro Suina, Takehito Shukuya, Fumiyuki Takahashi, Takuo Hayashi, Kieko Hara, Tsuyoshi Saito, Yoichiro Mitsuishi, Shoko Sonobe Shimamura, Wira Winardi, et al. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. Thoracic cancer. 2023. 14. 12. 1089-1097
Shiting Xu, Keita Miura, Takehito Shukuya, Sonoko Harada, Masahiro Fujioka, Wira Winardi, Shoko Shimamura, Kana Kurokawa, Issei Sumiyoshi, Taichi Miyawaki, et al. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. Cancers. 2023. 15. 4
Takafumi Handa, Takuo Hayashi, Ayako Ura, Isamu Watanabe, Kazuya Takamochi, Hiroko Onagi, Monami Kishi, Naohisa Matsumoto, Ken Tajima, Satsuki Kishikawa, et al. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Histopathology. 2023. 82. 6. 860-869
Yuki Tanabe, Takehito Shukuya, Yuichi Nagata, Takayasu Watanabe, Koichi Seto, Rina Takahashi, Koichi Masuda, Keita Miura, Ken Tajima, Makoto Hiki, et al. Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID-19 infection. Thoracic cancer. 2022. 13. 18. 2654-2658
Shoko Sonobe Shimamura, Takehito Shukuya, Tetsuhiko Asao, Daisuke Hayakawa, Kana Kurokawa, Shiting Xu, Keita Miura, Yoichiro Mitsuishi, Ken Tajima, Rina Shibayama, et al. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?. BMC cancer. 2022. 22. 1. 323-323

ｍore...

MISC (24)：

大熊智子, 三森友靖, 宿谷威仁, 増田孝一, 三浦啓太, 黒川加奈, 早川乃介, 徐仁美, 宮脇太一, 朝尾哲彦, et al. Retrospective study of steroid therapy to lung cancer patients with pneumonitis caused by immune checkpoint inhibitors (ICI). 日本呼吸器学会誌(Web). 2022. 11
舛井嘉大, 宿谷威仁, 片岡峻一, 阿部瞳, 黒川加奈, 中村育子, 宮脇太一, 濃沼淑芳, 朝尾哲彦, 金丸良太, et al. 進行非小細胞肺癌の治療成績向上に伴い異次性二次癌がどのような影響を与えているか?. 日本肺癌学会学術集会号. 2022. 63rd (CD-ROM)
嶋村尚子, 宿谷威仁, 朝尾哲彦, 早川乃介, 高遼, 光石陽一郎, 田島健, 嶋田奈緒子, 高橋史行, 高橋和久. Examination of long-term survival factors in advanced EGFR mutation/ALK fusion gene-positive NSCLC. 日本呼吸器学会誌(Web). 2021. 10
三浦啓太, 宿谷威仁, 朝尾哲彦, 虎澤匡洋, 早川乃介, 松本直久, 嶋村尚子, 高遼, 光石陽一郎, 田島健, et al. Efficacy of first line Pembrolizumab in recurrent non-small cell lung cancer after radical treatment. 日本呼吸器学会誌(Web). 2021. 10
松本直久, 岡田佐知子, 松田英利子, 神垣隆, 堀賢, 松田浩成, 黒川加奈, 早川乃介, 濃沼淑芳, 田島学, et al. 免疫チェックポイント阻害剤の長期予後予測因子の検討. 肺癌. 2018. 58. 6. 582-582

ｍore...

Professional career (1)：

博士 (順天堂大学)

Work history (1)：

2021/05 - 現在順天堂大学医学部・大学院医学研究科呼吸器内科准教授

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page